Fera Daniela, Lee Matthew S, Wiehe Kevin, Meyerhoff R Ryan, Piai Alessandro, Bonsignori Mattia, Aussedat Baptiste, Walkowicz William E, Ton Therese, Zhou Jeffrey O, Danishefsky Samuel, Haynes Barton F, Harrison Stephen C
Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Department of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC, 27710, USA.
Nat Commun. 2018 Mar 16;9(1):1111. doi: 10.1038/s41467-018-03565-6.
HIV-1 envelope (Env) mimetics are candidate components of prophylactic vaccines and potential therapeutics. Here we use a synthetic V3-glycopeptide ("Man-V3") for structural studies of an HIV Env third variable loop (V3)-glycan directed, broadly neutralizing antibody (bnAb) lineage ("DH270"), to visualize the epitope on Env and to study how affinity maturation of the lineage proceeded. Unlike many previous V3 mimetics, Man-V3 encompasses two key features of the V3 region recognized by V3-glycan bnAbs-the conserved GDIR motif and the N332 glycan. In our structure of an antibody fragment of a lineage member, DH270.6, in complex with the V3 glycopeptide, the conformation of the antibody-bound glycopeptide conforms closely to that of the corresponding segment in an intact HIV-1 Env trimer. An additional structure identifies roles for two critical mutations in the development of breadth. The results suggest a strategy for use of a V3 glycopeptide as a vaccine immunogen.
HIV-1包膜(Env)模拟物是预防性疫苗的候选成分和潜在的治疗药物。在此,我们使用一种合成的V3糖肽(“Man-V3”)对HIV Env第三个可变环(V3)-聚糖导向的广谱中和抗体(bnAb)谱系(“DH270”)进行结构研究,以可视化Env上的表位,并研究该谱系的亲和力成熟过程是如何进行的。与许多先前的V3模拟物不同,Man-V3包含V3-聚糖bnAb识别的V3区域的两个关键特征——保守的GDIR基序和N332聚糖。在我们对谱系成员DH270.6的抗体片段与V3糖肽复合物的结构研究中,与抗体结合的糖肽的构象与完整HIV-1 Env三聚体中相应片段的构象紧密相符。另一个结构确定了两个关键突变在广度发展中的作用。结果提示了一种将V3糖肽用作疫苗免疫原的策略。